Avantor is playing a pivotal role in partnering with organizations working on COVID-19 therapies
Devashish Ohri, Executive VP - India, Middle East & Africa (IMEA) elaborates on Avantor’s contributions to tackle the COVID-19…
Author
We need companies to apply access approaches more systematically, consistently and at a larger scale…
Claudia Martinez, Lead for the Access to Medicine Index shares more insights from this year's report and recommends steps to…
A strong and independent voice of the nutraceutical industry in the country is still lacking
Sushil Khaitan, CEO & Director at Purenutrition.in opines that given the size of the nutraceutical industry in India today, it…
We might need to redefine our approach to drug discovery and approval to be prepared for the future
Hitesh Windlass, MD, Windlas Biotech gives an overview of the changes bought by COVID-19 pandemic in the pharma industry, his…
What COVID-19 taught us
In this year-ender edition, experts reflect on the biggest lessons for India Pharma Inc from the current pandemic
Drug developers are interested in innovative polymers and multilayer technology to help meet…
Rajarshi Datta, Country Head & General Manager - South Asia, Honeywell Advanced Materials informs there is a growing need for…
India is a key market for us, it is a pharma centre of excellence
Alessandra Vizza, Regional Business Director, Corning Reactor Technologies talks about Advanced-Flow Reactors (AFR) and explains…
COVID-19 vaccine delivery: Prepping for challenge extraordinaire
India will have a very strategic role to play in ensuring universal access to COVID-19 vaccines. All stakeholders must step up…
COVID-19 has made online learning a credible source of education
Romola Pinto, who leads the Rubicon Academy team and also heads the HR function at Rubicon Research, speaks about the…
Express Pharma and Schneider Electric organise webinar on smart pharma packaging technologies
Experts share insights on how smart packaging technologies are evolving and the significant benefits they can bring to the pharma…